REVERSE-SD is a 6-month phase 2b clinical study designed to evaluate neflamapimod's activity in reversing synaptic dysfunction ("SD"), as assessed by tests of episodic memory in patients with mild Alzheimer's disease. 150 patients with mild Alzheimer's disease will be randomized on a double-blind basis to placebo or 40 mg of neflamapimod twice daily for 24 weeks. Inclusion criteria include Clinical Dementia Rating scale (CDR) 0.5 or 1.0 with documented memory deficit, MMSE 20 to 28, and positive AD-related cerebrospinal fluid biomarkers. The primary endpoint will be episodic memory, with secondary endpoints including CDR-SB, MMSE, and CSF biomarkers. Further details are available at clinicaltrials.gov through the link below.